Goldman Sachs analyst Andrea Tan reiterated a Buy rating and $45.00 price target on Day One Biopharmaceuticals (NASDAQ: DAWN)The analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE